Compare STAA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | MIRM |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | STAA | MIRM |
|---|---|---|
| Price | $23.41 | $77.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $24.56 | ★ $92.45 |
| AVG Volume (30 Days) | ★ 1.5M | 844.6K |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $230,591,000.00 | ★ $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | $21.97 | $19.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $13.50 | $36.88 |
| 52 Week High | $30.81 | $82.58 |
| Indicator | STAA | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 58.25 |
| Support Level | $22.97 | $77.99 |
| Resistance Level | $23.74 | $82.58 |
| Average True Range (ATR) | 1.11 | 3.33 |
| MACD | -0.08 | 0.71 |
| Stochastic Oscillator | 17.07 | 74.62 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.